Selinexor at ASH 2019

Jim Omel |

Relapsed/Refractory Multiple Myeloma (RRMM) patients often face difficult and diminishing treatment options. We have effective immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs,) and monoclonal antibodies ( (MoAbs), but what do patients do when these drugs lose effect? New immunotherapies such as CAR-T and BiTEs help patients late in their disease if they meet inclusion criteria. Also, clinical trials […]